Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 4:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 34 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Ranolazine 500 mg Clear all
Completed Phase 3 Interventional Results available

Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)

NCT01442038
View directory record Official record
Conditions
Coronary Artery Disease, Angina Pectoris
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
2,651 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
86
States / cities
Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Sep 26, 2026, 4:50 AM EDT
Completed Phase 3 Interventional

Effect of Ranolazine on Arrhythmias and Microvolt T- Wave Alternans (MVTWA) Patients With LV Dysfunction

NCT00998218
View directory record Official record
Conditions
Sudden Cardiac Death, Ventricular Arrythmias
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Aspirus Heart and Vascular Institute-Research and Education
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Wausau, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 8, 2012 · Synced Sep 26, 2026, 4:50 AM EDT
Not listed Phase 4 Interventional

Ranolazine, Ethnicity and the Metabolic Syndrome

NCT01304095
View directory record Official record
Conditions
Coronary Artery Disease, Angina, Metabolic Syndrome
Interventions
Ranolazine
Drug
Lead sponsor
Atlanta Heart Specialists, LLC
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Cumming, Georgia • Tucker, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Sep 26, 2026, 4:50 AM EDT
Completed Phase 4 Interventional Results available

Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular Dysfunction

NCT02133352
View directory record Official record
Conditions
Pulmonary Hypertension, Diastolic Left Ventricular Dysfunction
Interventions
Ranolazine
Drug
Lead sponsor
Boston University
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Sep 26, 2026, 4:50 AM EDT
Completed Phase 3 Interventional Results available

Ranolazine Implantable Cardioverter-Defibrillator Trial

NCT01215253
View directory record Official record
Conditions
Ischemic Cardiomyopathy, Nonischemic Cardiomyopathy, Heart Failure
Interventions
Ranolazine
Drug
Lead sponsor
University of Rochester
Other
Eligibility
21 Years and older
Enrollment
1,012 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
83
States / cities
Tucson, Arizona • Little Rock, Arkansas • East Palo Alto, California + 70 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2018 · Synced Sep 26, 2026, 4:50 AM EDT
Terminated Phase 2 Interventional Results available

Evaluation of Exercise Treadmill Test (ETT) Indices in Participants With Cardiovascular Disease

NCT01562041
View directory record Official record
Conditions
Atherosclerotic Coronary Vascular Disease
Interventions
Ranolazine 500 mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Jacksonville, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2021 · Synced Sep 26, 2026, 4:50 AM EDT
Completed Phase 4 Interventional Results available

Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina

NCT01425359
View directory record Official record
Conditions
Angina Pectoris, Coronary Artery Disease, Type 2 Diabetes Mellitus
Interventions
Ranolazine, Ranolazine placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
949 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
20
States / cities
Little Rock, Arkansas • Merced, California • Moreno Valley, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Sep 26, 2026, 4:50 AM EDT
Completed Phase 4 Interventional Results available

Ranolazine and Microvascular Angina by PET in the Emergency Department

NCT02052011
View directory record Official record
Conditions
Microvascular Angina
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
30 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Sep 26, 2026, 4:50 AM EDT
Completed Phase 1 Interventional

Single Cohort 4-period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine

NCT01546597
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Metformin, Ranolazine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
30 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2012 · Synced Sep 26, 2026, 4:50 AM EDT
Completed Phase 3 Interventional Results available

Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD

NCT01754259
View directory record Official record
Conditions
Diabetes, Type I, Diabetes, Type II, Angina, Coronary Artery Disease
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 23, 2017 · Synced Sep 26, 2026, 4:50 AM EDT
Terminated Phase 2 Interventional Results available

Reduce Crohn's-Associated Diarrhea With Sodium Channel Therapy

NCT04456517
View directory record Official record
Conditions
Crohn's Disease, Inflammatory Bowel Disease
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Sep 26, 2026, 4:50 AM EDT
Completed Phase 3 Interventional Results available

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

NCT01494987
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Ranolazine, Placebo, Glimepiride, Diet, Exercise
Drug · Behavioral
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
46
States / cities
Mesa, Arizona • Tucson, Arizona • Pine Bluff, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2014 · Synced Sep 26, 2026, 4:50 AM EDT
Terminated Phase 4 Interventional Results available

Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy

NCT00832572
View directory record Official record
Conditions
Coronary Artery Disease, Pain, Peripheral Nervous System Diseases, Polyneuropathy
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Houma, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 29, 2014 · Synced Sep 26, 2026, 4:50 AM EDT
Completed Phase 1 Interventional

Single Cohort, 2-Period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg

NCT01546558
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Metformin, Ranolazine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
30 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 10, 2012 · Synced Sep 26, 2026, 4:50 AM EDT
Completed Phase 4 Interventional Results available

Effect of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging

NCT01221272
View directory record Official record
Conditions
Myocardial Perfusion Imaging, Myocardial Ischemia
Interventions
Ranolazine, Placebo to match ranolazine, SPECT MPI, Exercise
Drug · Procedure · Behavioral
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
26
States / cities
Birmingham, Alabama • Imperial, California • Lincoln, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2014 · Synced Sep 26, 2026, 4:50 AM EDT
Completed Phase 3 Interventional Results available

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

NCT01472185
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Ranolazine, Placebo, Diet, Exercise
Drug · Behavioral
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
57
States / cities
Glendale, Arizona • Phoenix, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2014 · Synced Sep 26, 2026, 4:50 AM EDT
Not listed No phase listed Observational

Impact of Ranolazine on Myocardial Ischemia Detected by High-Field 3T Cardiovascular Magnetic Resonance (CMR) Imaging and P-31 Spectroscopy

NCT01804543
View directory record Official record
Conditions
Angina, Heart Disease
Interventions
Ranolazine
Drug
Lead sponsor
Westside Medical Associates of Los Angeles
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Sep 26, 2026, 4:50 AM EDT
Terminated Phase 3 Interventional Results available

Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery

NCT01352416
View directory record Official record
Conditions
Heart; Dysfunction Postoperative, Cardiac Surgery
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
22 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Royal Oak, Michigan • Troy, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 5, 2017 · Synced Sep 26, 2026, 4:50 AM EDT
Not listed Phase 4 Interventional

Study to Reduce Symptoms of Premature Beats With Ranolazine

NCT01996618
View directory record Official record
Conditions
Premature Ventricular Beats
Interventions
Ranolazine
Drug
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Sep 26, 2026, 4:50 AM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients

NCT01435174
View directory record Official record
Conditions
End-stage Renal Disease, Cardiovascular Disease
Interventions
Ranolazine, Pharmacokinetic Blood and Dialysate Sampling, QT Interval
Drug · Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 74 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 15, 2017 · Synced Sep 26, 2026, 4:50 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis

NCT03472950
View directory record Official record
Conditions
ALS
Interventions
Ranolazine 500 MG, Ranolazine 1000 MG
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2024 · Synced Sep 26, 2026, 4:50 AM EDT
Terminated Not applicable Interventional

Effect of Ranolazine on Echocardiographic Indices of Diastolic Dysfunction

NCT00574756
View directory record Official record
Conditions
Ranolazine, Diastolic Heart Failure, Tissue Doppler Ultrasound, Echocardiography
Interventions
ranolazine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Sep 26, 2026, 4:50 AM EDT
Completed Phase 4 Interventional Results available

Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome

NCT02252406
View directory record Official record
Conditions
Stable Angina, Metabolic Syndrome
Interventions
Ranolazine, Placebo
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
30 Years to 75 Years · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Sep 26, 2026, 4:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

CiPA Phase 1 ECG Biomarker Validation Study

NCT03070470
View directory record Official record
Conditions
Drug-induced QT Prolongation, Pharmacokinetics, Pharmacodynamics
Interventions
Ranolazine, Verapamil, Lopinavir / Ritonavir, Chloroquine, Placebo, Dofetilide and Diltiazem
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 26, 2026, 4:50 AM EDT